Skip to main content
GEDSF logo

Gedeon Richter PLC (GEDSF) Stock Price & Analysis

Gedeon Richter PLC (GEDSF) — price $24.85 (0.00%), as of the Nov 19, 2026 trading session; market cap $4.53B.

Educational signal · not a buy or sell recommendation · How to read this

$24.85 $0.00 (0.00%) Market Cap $4.53B

Gedeon Richter PLC · GEDSF

Gedeon Richter PLC is a Hungarian pharmaceutical company engaged in the development, manufacture, and distribution of pharmaceutical products, operating through distinct segments including Pharmaceuticals, Wholesale & Retail, and Other support services.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • SUPN · Supernus Pharmaceuticals, Inc. · 74 /100
  • BHC · Bausch Health Companies Inc. · 30 /100
  • LNTH · Lantheus Holdings, Inc. · 96 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$24.85
Change on the day0.00%
Market capitalisation$4.53B—
Price / earnings (trailing)10.83
Shares traded on the day518

Price & events

Other perspectives

Council score for Gedeon Richter (GEDSF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Undervalued
Profit Margin Strong
Revenue Growth Weak
Debt/Equity Strong
ROE Moderate
Gross Margin Strong

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 16, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Gedeon Richter (GEDSF), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Gedeon Richter PLC (GEDSF) is the company analyzed here. It employs 11,155 people. In Q1 FY2026 it reported revenue of HUF 223.93B and net income of HUF 66.39B. The market values it at $4.53B.

2 · Latest results

What do the latest results show for Gedeon Richter (GEDSF)?

Short answer · as of

The most recent reported quarter, Q1 FY2026, carried revenue of HUF 223.93B.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q1 FY2026HUF 223.93BHUF 66.39BHUF 363.99 (diluted)
Q4 FY2025HUF 245.33BHUF 68.06BHUF 372.79 (diluted)
Q3 FY2025HUF 209.80BHUF 42.36BHUF 231.45 (diluted)
Q2 FY2025HUF 241.49BHUF 51.84BHUF 283.75 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Gedeon Richter (GEDSF)?

Short answer · as of

The distress and quality screens read Altman Z 5.35 · Piotroski F 6. Trailing ratios: ROE 16.7% · ROA 13.0% · current ratio 4.69 · earnings yield 9.3% · free-cash-flow yield 10.5%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held GEDSF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported GEDSF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Gedeon Richter Stock: Key Questions Answered

These answers are editorial: 1 of these 8 answers is drawn from the GEDSF research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is GEDSF a good stock to buy?

Stock Expert AI does not rate GEDSF buy, sell or hold. Gedeon Richter PLC has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the GEDSF stock price today?

The last price recorded for Gedeon Richter PLC (GEDSF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for GEDSF?

Gedeon Richter PLC faces several key risks inherent to the pharmaceutical industry and its operational structure. These include the high costs and uncertainties associated with pharmaceutical research and development, where clinical trial failures can lead to substantial financial losses.

What are the key factors to evaluate for GEDSF?

Evaluate GEDSF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Expansion into New Therapeutic Areas: Gedeon Richter's ongoing investment in its Pharmaceutical segment's research and development capabilities presents a significant opportunity to diversify its product portfolio into new, high-growth therapeutic areas. Not financial advice.

How frequently does GEDSF data refresh on this page?

GEDSF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven GEDSF's recent stock price performance?

Gedeon Richter PLC (GEDSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider GEDSF overvalued or undervalued right now?

The trailing P/E of Gedeon Richter PLC (GEDSF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research GEDSF before investing?

Before investing in Gedeon Richter PLC (GEDSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 12 figures on this page — 9 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.